Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

febrile neutropenia/phosphatase

Линкът е запазен в клипборда
СтатииКлинични изследванияПатенти
Страница 1 от 21 резултата

Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
To assess population pharmacokinetics (PK) and pharmacodynamics (PD) of both piperacillin and tazobactam in neutropenia patients and examine dosage requirements related to the MIC distribution for Gram-negative bacteria involved in bloodstream infections

Influence of febrile neutropenia period on plasma viscosity at malignancy.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
Cancer, chemotherapy, and infections all together make changes in blood rheology and may affect the defense mechanisms by changing the thrombocyte function and endothelial cell. We have examined changes of blood rheology on plasma viscosity to put on probable following criteria for starting the

Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE Febrile neutropenia is a serious complication among cancer patients receiving myelosuppressive chemotherapy. Patient-specific risk factors, chemotherapy-related and disease-related characteristics can affect the clinical outcome and management of febrile neutropenia. Although many factors

[Results of a post-marketing surveillance of meropenem for febrile neutropenia].

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
The post-marketing surveillance of meropenem (Meropen) for febrile neutropenia (FN) was conducted between July 2010 and June 2012 to evaluate safety and efficacy under actual clinical use. There were 1191 and 1124 evaluable cases for safety and efficacy respectively, of 1207 case cards collected

Efficacy of intravenous ciprofloxacin in patients with febrile neutropenia refractory to initial therapy.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
We previously reported that monotherapy with carbapenem or cefepime exhibited efficacy equivalent to cefepime plus an aminoglycoside as initial therapy for febrile neutropenia (FN), achieving an adequate response in two-thirds of the patients. However, only one-third of the remaining poor responders

A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
A high intermittent dose regimen (group A: 10 mg kg(-1) on day 1, 5 mg kg(-1) on days 3 and 6) was compared with standard dosing (group B: 3 mg kg(-1) per day for 14 days) of liposomal amphotericin B (LAB) for empirical treatment of persistent febrile neutropenia. A total cumulative dose of 1275 mg

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
The aim of this investigation was to assess retrospectively docetaxel safety and efficacy in advanced breast cancer patients in a French compassionate use programme. Patients had received > 1 prior chemotherapy regimen for advanced disease, were either anthracycline-resistant (that is progressed

Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND Randomized studies have shown improved survival with the combination of docetaxel (D) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). We retrospectively investigated whether coadministration of low-dose glucocorticoids has clinical

Hepatosplenic fungal infection in adult patients with acute leukemia.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND Hepatosplenic fungal infection is an important infectious complication in adult patients with acute leukemia. METHODS From 2001 to 2004, 163 adult patients were diagnosed with acute leukemia at our center: 41 patients had acute lymphoblastic leukemia (ALL) and 122 patients had acute

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE The primary aims of this phase I-II study were to determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary efficacy of the combination of docetaxel and the endothelin A receptor antagonist atrasentan as first-line treatment for men with metastatic

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND The California Cancer Consortium completed a phase I trial of E7389 (eribulin mesylate), an analog of the marine natural product halichondrin B. This trial was to determine the pharmacodynamics, pharmacokinetics, and MTD of E7389 administered by bolus injection weekly for 3 weeks out of

Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND Gemcitabine combined with carboplatin (CG) is one of the regimens used widely for advanced non-small cell lung cancer. Improvement in its toxicity may result in good clinical outcomes. METHODS A new schedule of gemcitabine and carboplatin (CG8) was compared with the standard one (CG1).

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
OBJECTIVE To determine the recommended dose (RD) and the pharmacokinetic profile of irinotecan and its metabolites in cancer patients with hyperbilirubinemia. METHODS Patients were assigned to four treatment groups according to their baseline total bilirubin level. Patients in group I (bilirubin

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
Maximum tolerated dose (MTD), recommended dose (RD), and pharmacokinetics (PK) were evaluated for trabectedin 3-h every-3-weeks schedule in 33 cancer patients stratified according to liver dysfunction degree as per baseline alkaline phosphatase (AP). Stratification was as follows: stratum I [upper

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND Aviscumine is an Escherichia coli-derived recombinant type II ribosome-inactivating protein with potent antitumor activity in vitro and in vivo. It is the recombinant counterpart of natural mistletoe lectin-I. The current study was performed to determine the safety profile, dose-limiting
Присъединете се към нашата
страница във facebook

Най-пълната база данни за лечебни билки, подкрепена от науката

  • Работи на 55 езика
  • Билкови лекове, подкрепени от науката
  • Разпознаване на билки по изображение
  • Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
  • Прочетете научни публикации, свързани с вашето търсене
  • Търсете лечебни билки по техните ефекти
  • Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания

Google Play badgeApp Store badge